Tactile Systems Technology Inc（TCMD）の財務TCMDTactile Systems Technology Inc

Tactile Systems Technology, Inc. (TCMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lymphedema products, accounting for 85.9% of total sales, equivalent to $73.63M. Another important revenue stream is Airway clearance products. Understanding this composition is critical for investors evaluating how TCMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Tactile Systems Technology, Inc. maintains a gross margin of 75.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.97%, while the net margin is 9.08%. These profitability ratios, combined with a Return on Equity (ROE) of 11.88%, provide a clear picture of how effectively TCMD converts its operational activities into shareholder value.

In the context of the broader market, TCMD competes directly with industry leaders such as SSII and DCTH. With a market capitalization of $501.07M, it holds a significant position in the sector. When comparing efficiency, TCMD's gross margin of 75.50% stands against SSII's 48.46% and DCTH's 89.75%. Such benchmarking helps identify whether Tactile Systems Technology, Inc. is trading at a premium or discount relative to its financial performance.

Tactile Systems has demonstrated strong financial performance with Q2 2026 revenue of $85.7 million and a gross margin of 76.3%. The company has also raised its full-year revenue guidance for 2026 to between $360 million and $366 million, reflecting confidence in future growth.